Business
SPEC: Losses widened in Q3 as SpectraCure advances clinical studies and seeks new funding
SPEC: Losses widened in Q3 as SpectraCure advances clinical studies and seeks new funding
About this update from Spectracure Ab
Q3 2024 saw continued clinical progress and strategic planning for SpectraCure, but losses widened and liquidity remains a concern as new studies increase funding needs. The company is seeking additional financing to support ongoing development. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.